You are here:
Roche Pharma India Launches Patient Support App To Help Patients Seamlessly Navigate Their Care Journey
Roche expands its Global Analytics and Technology Center of Excellence.
Roche's Evrysdi (Risdiplam) - the first and only oral treatment for adults and children two months or older suffering from Spinal Muscular Atrophy (SMA) now available in India.
Roche’s Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India
Roche receives Emergency Use Authorisation in India for its investigational Antibody Cocktail (Casirivimab and Imdevimab) used in the treatment of Covid-19
Company statement on Tocilizumab (Brand: Actemra) supplies
US-FDA Approved Foundation Medicine's foundationone®Liquid cdx, a Pan-Tumor Liquid Biopsy Genomic Test for Late Stage Cancer Patients now Available in India
Roche Pharma India expands partnership with Cipla to further improve access to key oncology medicines
Roche Pharma India partners with Entero Healthcare Solutions to improve access to nephrology medicines
V. Simpson Emmanuel appointed as General Manager, Roche Products (India) Pvt. Ltd.
Roche’s Atezolizumab receives DCGI approval for treatment of metastatic triple-negative breast cancer in India
Roche’s Atezolizumab receives DCGI approval for treatment of extensive-stage small cell lung cancer in India
Roche launches new therapy Emicizumab for people with Hemophilia A on World Hemophilia Day
Roche and St. Jude India ChildCare Centre come together with Dr. B Barooah Cancer Institute to offer holistic cancer care to underprivileged children
Roche Pharma India partners with Cipla to create greater access to key medicines
Key statement on the emergency use authorisation and supply of the investigational antibody cocktail casirivimab and imdevimab in India.
Roche's statement on Tocilizumab (Actemra) supplies
An Opportunity for India: Improving Transparency
Providing confidence and support to patients
Approval of biosimilars must be subject to rigorous clinical and regulatory standards.
Company Statement: Delhi High Court Interim Order, March 03, 2017